|
**Overview**: Leukemia Comprehensive 6 Markers Panel**Introduction**: The Leukemia Comprehensive 6 Markers Panel is a diagnostic tool designed for comprehensive leukemia screening using whole blood or bone marrow samples. In India, acute leukemias (ALL ~3-4 per 100,000 children, AML ~2-3 per 100,000 adults) and chronic leukemias (CML, CLL) contribute to ~50,000â€"60,000 new cases annually, with high mortality in rural/low-SES populations due to delayed diagnosis. High burden from under-testing leading to late presentation, poor risk stratification, and inappropriate chemotherapy. Per hematology practices aligned with ICMR and Indian Society of Haematology & Blood Transfusion guidelines, the test employs flow cytometry and PCR for 62 leukemia markers (CD34, CD13, CD33, CD117, CD19, CD10, CD20, TdT, MPO, etc.) over 1-2 days with high accuracy, valuable for lineage assignment, subtype classification, and minimal residual disease monitoring. This diagnostic falls under leukemia screening and targets patients with unexplained cytopenias, blasts, or lymphadenopathy, addressing accurate detection to guide induction chemotherapy, targeted therapy (imatinib in CML), or HSCT. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise immunophenotyping and improving leukemia survival. Its blood/bone marrow-based approach ensures reliable multi-marker analysis.**Other Names**: Leuk Comp 6 Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/hematology/oncology/cytogenetics, compliant with 2025 standards.**Historical Milestone**: Extended flow panel standard; in India, routine in leukemia centers.**Purpose**: The test assesses 62 parameters including leukemia markers to guide comprehensive screening, classify lineage/subtype, inform therapy.**Test Parameters**: 1â€"62. Leukemia Markers (CD34, CD13, CD33, CD117, etc.).**Pretest Condition**: No fasting required; patients should have blasts or cytopenias.**Specimen**: 3 mL whole blood or bone marrow in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve cell viability, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for flow/PCR).**Medical History**: Patients should provide details on fever, bleeding, lymphadenopathy.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed leukemia including progression, benefits of profiling, and minimal discomfort from sampling.**Procedural Considerations**: The test involves sample processing using flow cytometry/PCR by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low cell count can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Aberrant marker expression confirms leukemia subtype, necessitating specialist input.**Specialist Consultation**: Hematologists/oncologists should be consulted for management.**Additional Supporting Tests**: Cytogenetics, molecular (BCR-ABL) for confirmation.**Test Limitations**: Requires viable cells; comprehensive approach required.**References**: Indian Journal of Hematology 2024, Leukemia Studies India 2023. |
